What is he best known for?
The fields of study he is best known for:
Ashok B. Kulkarni mostly deals with Cell biology, Immunology, Cyclin-dependent kinase 5, Transforming growth factor beta and Molecular biology.
His Cell biology study integrates concerns from other disciplines, such as Dentin sialoprotein, Dentin sialophosphoprotein, Dentin phosphoprotein, Amelogenesis and Dentinogenesis.
His work carried out in the field of Immunology brings together such families of science as Cancer research and TGF beta 1.
His studies deal with areas such as Cerebral cortex, Neuroscience and Cyclin-dependent kinase as well as Cyclin-dependent kinase 5.
His study in Transforming growth factor beta is interdisciplinary in nature, drawing from both Basal, Knockout mouse, Cytokine and Ratón.
The study incorporates disciplines such as Mutant, MAP2K7, Gene targeting, MAP kinase kinase kinase and ASK1 in addition to Molecular biology.
His most cited work include:
- Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. (1652 citations)
- Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice (923 citations)
- Targeted disruption of the cyclin-dependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death. (815 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Cell biology, Molecular biology, Cyclin-dependent kinase 5, Immunology and Amelogenin.
His primary area of study in Cell biology is in the field of Transforming growth factor.
Ashok B. Kulkarni studied Molecular biology and Dentin sialophosphoprotein that intersect with Dentin mineralization.
Ashok B. Kulkarni interconnects Neuroscience and Kinase activity in the investigation of issues within Cyclin-dependent kinase 5.
His studies in Immunology integrate themes in fields like Head and neck squamous-cell carcinoma, Cancer research and Transforming growth factor beta.
The concepts of his Amelogenin study are interwoven with issues in Amelogenesis, Ameloblast and Amelogenesis imperfecta.
He most often published in these fields:
- Cell biology (36.15%)
- Molecular biology (25.82%)
- Cyclin-dependent kinase 5 (23.47%)
What were the highlights of his more recent work (between 2015-2019)?
- Head and neck squamous-cell carcinoma (9.86%)
- Cancer research (13.15%)
- Immune system (7.51%)
In recent papers he was focusing on the following fields of study:
Ashok B. Kulkarni mainly investigates Head and neck squamous-cell carcinoma, Cancer research, Immune system, Immunotherapy and Immunology.
As a part of the same scientific study, Ashok B. Kulkarni usually deals with the Immune system, concentrating on Antibody and frequently concerns with Tumor microenvironment, Tissue microarray, Immunosurveillance and Cell growth.
His Immunology research integrates issues from Mucolipidosis type IV, Fabry disease and Neurology.
Cell biology is closely connected to Stromal cell in his research, which is encompassed under the umbrella topic of T cell.
Ashok B. Kulkarni has included themes like Genetically modified mouse and Activator in his Cell biology study.
As part of one scientific family, Ashok B. Kulkarni deals mainly with the area of Phosphorylation, narrowing it down to issues related to the Receptor, and often Cyclin-dependent kinase 5.
Between 2015 and 2019, his most popular works were:
- STAT3 Induces Immunosuppression by Upregulating PD-1/PD-L1 in HNSCC: (57 citations)
- Blockade of adenosine A2A receptor enhances CD8 + T cells response and decreases regulatory T cells in head and neck squamous cell carcinoma (54 citations)
- LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma. (52 citations)
In his most recent research, the most cited papers focused on:
Ashok B. Kulkarni mainly focuses on Head and neck squamous-cell carcinoma, Immune system, Immunotherapy, CD8 and Immunology.
His Head and neck squamous-cell carcinoma research integrates issues from Immune checkpoint and Cancer research.
Ashok B. Kulkarni interconnects Innate immune system, Cystic fibrosis, Immunity and Degranulation in the investigation of issues within Cancer research.
His Immunotherapy research is multidisciplinary, relying on both Cytotoxic T cell and PTEN.
His CD8 research incorporates elements of Internal medicine and Oncology.
His research related to Acquired immune system and Inflammation might be considered part of Immunology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
